My ISA Watch List: GlaxoSmithKline plc, Diageo plc And PZ Cussons plc

Why I’m watching GaxoSmithKline plc (LON: GSK), Diageo plc (LON: DGE) and PZ Cussons plc (LON: PZC) for this year’s ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

From 6 April 2016, we get another ISA allowance of £15,240, and that’s a tax-free investment opportunity worth grabbing.

Leading with quality

I’m looking for firms that can pay a reliable and growing stream of dividends in the years to come. If the company has a quality business with strong cash flow, capital growth should follow. Expanding dividend payments and a rising share price mean a double win that should drive pleasing total returns.

Quality firms can go on my watch list waiting for a sensible entry point, such as during periods of general market weakness, or when a temporary issue knocks the firm’s share price.

Today’s focus is on GlaxoSmithKline (LSE: GSK), Diageo (LSE: DGE) and PZ Cussons (LSE: PZC). 

Defensive attributes

These firms attract because of their defensive qualities. GlaxoSmithKline, the pharmaceutical giant, trades in an industry characterised by consistent demand, and people often repeat-purchase the firm’s products. That set-up tends to generate reliable flows of cash for GlaxoSmithKline. Meanwhile, Diageo’s alcoholic drinks output also feeds into a consumer-driven market. People come back repeatedly for their favourite tipple and that translates into a reliable cash stream for Diageo.

PZ Cusson’s portfolio of consumable goods brands in the personal care, home care, beauty, food and nutrition markets is also a great cash generator. The common theme linking these three firms is that they all sell stuff that people need over and over again, profitably.

Outlooks

In February, GlaxoSmithKline’s chief executive said: “For 2016, we continue to expect core EPS percentage growth to reach double-digits on a constant currency basis, although we are also mindful that the macroeconomic and healthcare environment will continue to be challenging.”

Despite possible headwinds, GlaxoSmithKline looks set to lumber through 2016 and beyond. The firm announced a special dividend for 2015 and that strikes me as a good indicator that the firm remains in good health.

In January, Diageo’s chief executive said: “While trading conditions remain challenging in some markets, Diageo’s brands, capabilities in marketing and innovation and our route to consumer have proved resilient. I am confident that Diageo can deliver improved, sustained performance.”

Diageo’s top man is confident that the drinks provider can keep powering forward and so am I. The firm operates in an attractive industry and enjoys substantial economic moats with its popular brands.

Commenting on the firm’s interim results in January, PZ Cussons’ chairman said: These are a steady set of results in what have been challenging markets with overall revenue and profitability broadly flat versus the comparative period. We remain confident about the medium and long-term opportunities which should begin to materialise.”

I’m also confident that PZ Cussons’ business model will keep it afloat and steady in difficult times, and growing nicely in the good times.

All three of these firms operate good quality, cash-generating and enduring businesses, and because of that, their valuations tend to look a little pricey at times. However, buying on dips, down days and during times of general market malaise can be one way of building up a position in the longer-term growth stories on offer. That’s why I think they’re good candidates for my ISA watch list.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of PZ Cussons. The Motley Fool UK has recommended Diageo and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After a positive Q4 update, is the Vistry share price set to bounce back?

The Vistry share price has been falling sharply as a result of cost issues in its South Division. But the…

Read more »

Investing Articles

Is it game over for the Diageo share price?

The Diageo share price is showing as much spirit as an alcohol-free cocktail. Harvey Jones is wondering whether he should…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 key reasons why AstraZeneca’s share price looks a steal to me right now

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be…

Read more »

Investing Articles

Here’s how investors could aim for a £6,531 annual passive income from £11,000 of Aviva shares

As a stock’s yield rises when its price falls, I'm not bothered by Aviva shares’ apparent inability to break the…

Read more »

Investing Articles

3 million reasons why earning a second income is more important than ever

With AI posing a threat to UK jobs, our writer considers ways to earn a second income by investing in…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

With an 8% yield, is the second-largest FTSE 250 stock worth considering?

Our writer considers the value of the second-largest stock on the FTSE 250 with a £4bn market cap and a…

Read more »

Close-up of British bank notes
Investing Articles

10%+ dividend yields! 3 top dividend shares to consider in 2025!

Investing in these high-yield UK dividend shares could deliver a huge passive income for years to come. Royston Wild explains…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Greggs’ share price tanked last week. So I bought more!

Could Greggs be one of the FTSE 250's best bargains following its share price slump? Royston Wild thinks so, as…

Read more »